ADP vs HCM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ADP is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ADP and HCM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ADP and HCM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Automatic Data Processing (ADP) is a Roseland, New Jersey-based global technology company providing cloud-based human capital management (HCM) and payroll solutions to businesses of every size, from single-employee firms using ADP RUN to large multinationals using ADP Workforce Now and Lyric. The company operates through two primary segments: Employer Services, which covers payroll processing, tax filing, benefits administration, talent management, time and attendance, and compliance; and Professional Employer Organization (PEO) Services, under the ADP TotalSource brand, which co-employs client workers to deliver Fortune 500-level benefits packages to smaller firms. ADP also earns a meaningful stream of interest income by holding and investing the client funds it collects between payroll runs before remitting them to employees and tax authorities. Founded in 1949 by Henry Taub and Frank Lautenberg as a manual payroll processor and taken public in 1961, ADP pioneered computerized payroll in the 1960s and grew through decades of acquisitions and organic expansion into its present position as the market leader in global payroll software with roughly 9.9% market share. The company is led by President and CEO Maria Black, who took the helm in 2023, and employs approximately 67,000 people worldwide. ADP's fiscal year ends June 30, and its shares trade on the Nasdaq under the ticker ADP.

Full ADP guide

HUTCHMED (China) Limited trades on Nasdaq as ADSs under HCM, on the Hong Kong Stock Exchange as stock code 13, and on London's AIM market. It discovers and develops targeted oncology and immunology therapies in China and increasingly commercializes them globally through partners. Its marketed portfolio includes fruquintinib (sold as ELUNATE in China with Eli Lilly and as FRUZAQLA outside China with Takeda), surufatinib (SULANDA) for neuroendocrine tumors, and savolitinib (ORPATHYS) partnered with AstraZeneca. A separate Other Ventures segment, mainly prescription drug distribution in China, contributed ~$116 million of revenue in the first half of 2026 and is a lower-margin, non-innovative business that inflates headline revenue relative to the drug franchise.

Full HCM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ADP drivers: Sticky recurring revenue and elite client retention; AI-powered platform evolution expanding wallet share.
• HCM drivers: ATTC platform licensing as the value unlock; China commercial rebound and fruquintinib's geographic spread.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: ADP's growth is materially sensitive to employment levels and interest rates: a recession that raises unemployment reduces the headcount on which per-employee fees are charged, crimps new-business bookings, and may accelerate small-business client failures, while falling rates shrink the float income earned on client funds held between payroll cycles. For HCM, most of HUTCHMED's product economics run through partners, so Takeda, Eli Lilly and AstraZeneca decisions on pricing, launch pace and promotion shape results more than HUTCHMED's own execution does.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ADP if you believe its drivers more; HCM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ADP and HCM guides.

ADP. ADP's trailing P/E of roughly 20x represents a meaningful discount to both its own five-year average of approximately 29-30x and to the broader software sector, reflecting a combination of share-price weakness from its 52-week high near $316 and accelerating earnings growth. The adjusted EBIT margin of 26% in fiscal 2025, expanding 50 basis points year-over-year, demonstrates operating leverage even as the company invests heavily in AI and global platform development. Management has guided for fiscal 2026 revenue growth of 5% to 6% and adjusted diluted EPS growth of 8% to 10%, implying continued margin expansion through productivity gains and the lapping of acquisition-related costs.

HCM. The headline revenue number is misleading on its own because ~$116 million of first-half 2026 revenue came from the low-margin Other Ventures drug distribution segment rather than innovative medicines; the oncology and immunology franchise generated ~$162.3 million, of which ~$40.9 million was milestone, royalty and R&D service income including an ~$18.1 million payment from Eli Lilly. Profitability is genuine but slim, with R&D of ~$78.8 million in the half consuming most of the gross profit. Because net cash covers roughly half the market value, valuation multiples on the operating business look far lower than a screener showing price-to-sales on the consolidated figure would suggest.

Headline figures (approximate, 2026-06-27): ADP shows revenue (fy2025, ended june 30, 2025) ~$20.6 billion, revenue (ttm, trailing twelve months to mar 2026) ~$21.6 billion, net income (fy2025) ~$4.1 billion, adjusted diluted eps (fy2025) ~$10.01; HCM shows market capitalization ~$2.4B (ADS ~$14, ~173M ADSs, each ADS = 5 ordinary shares), revenue (ttm) ~$549M (FY2025 ~$548.5M; H1 2026 ~$278.3M vs ~$277.7M in H1 2025), net income attributable (ttm) ~$18M (H1 2026 ~$15.9M; the ~$455M H1 2025 figure was mostly a one-off SHPL divestment gain), cash and short-term investments ~$1.37B at June 30, 2026, against ~$95M of bank borrowings.

ADP and HCM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ADP and HCM exposure against your real portfolio. It is not an investment adviser.